Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

AstraZeneca · Phase 2 · Terminated · Enrollment 213

NCT01235741

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Group An/rn/rn/rn/r
Group Bn/rn/rn/rn/r
Placebon/rn/rn/rn/r
Pramlintide + Metreleptinn/rn/rn/rn/r

Not shown

  • Group A: endpoint not reported
  • Group B: endpoint not reported
  • Placebo: endpoint not reported
  • Pramlintide + Metreleptin: endpoint not reported